iRhythm Holdings, Inc. IRTC R2K

Healthcare · Medical Devices · United States

https://www.irhythmtech.com

iRhythm Holdings, Inc., a digital healthcare company, engages in the design, development, and commercialization of device-based technology that provides ambulatory cardiac monitoring services to diagnose arrhythmias in the United States. The company offers Zio ambulatory cardiac monitoring services, including long-term and short-term continuous monitoring and mobile cardiac telemetry monitoring services. It also provides Zio Monitor System, a prescription-only remote electrocardiogram (ECG) monitoring system consisting a patch ECG monitor that records the electric signal from the heart continuously for up to 14 days; Zio XT System, a prescription-only remote ECG monitoring system that consists of the Zio XT patch that records the electric signal from the heart continuously for up to 14 days; and Zio ECG Utilization Software System, which supports the capture and analysis of ECG data. In addition, the company offers Zio AT System, a prescription-only remote ECG monitoring system, which consists of the Zio AT patch that records the electric signal from the heart continuously for up to 14 days, as well as incorporates the Zio AT wireless gateway to provide connectivity between the patch and the ZEUS System during the patient wear period. It has a development collaboration agreement with BioIS to develop and commercialize pulse oximetry, accelerometry, and trending non-invasive blood pressure technologies for use within ambulatory cardiac monitoring products and services. The company was formerly known as iRhythm Technologies, Inc. and changed its name to iRhythm Holdings, Inc. in January 2026. iRhythm Holdings, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.

Market & Price

Market Cap

$3.74B

Current Price

$113.90

High / Low (52W)

$189.25 / $110.94

Beta

1.33

Valuation

Stock P/E

Industry PE

23.65

Forward P/E

108.34

PEG Ratio

Book Value

$4.91

Price to Book

23.21

P/S

4.75

EV/EBITDA

-351.34

Dividend Yield

Profitability & Returns

ROCE

-3.51%

ROE

-22.42%

ROA

-1.15%

Profit Margin

-3.53%

Op Margin

-5.95%

EPS (Latest Qtr)

$-0.43

EPS (TTM)

$-0.85

Balance Sheet & Liquidity

Debt/Equity

4.52

Quick Ratio

4.79

Current Ratio

5.17

Debt

$729.29M

Total Assets

$1.02B

Current Assets

$702.76M

Working Capital

$550.88M

Ownership

Promoter Holding

1.12%

Chg in Prom Hold

FII / Inst Holding

110.95%

Chg in FII Hold

Financial Snapshot

Enterprise Value

$3.92B

Total Revenue (TTM)

$787.85M

EBITDA

$-11.16M

Free Cash Flow

$57.02M

Operating Cash Flow

$62.58M

Shares Outstanding

32.86M

Gross Margin

71.00%

Payout Ratio

0.00%

Growth (CAGR)

Revenue 5Y

22.05%

Profit 5Y

20.55%

Revenue (YoY)

25.70%

Earnings (YoY)

PROS

Compounding revenue at 22.1% over 5 years.
Profit CAGR of 20.5% over 5 years.
Generates positive free cash flow.

CONS

Trading 39.8% below its 52-week high.
In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

Price Chart

Robinhood TradingView StockAnalysis

Fundamental Growth

Period: Metric:

Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).

Peer comparison

Peer companies in the same sector (Healthcare).

#	Name	CMP $	P/E	Mkt Cap	Div Yld %	ROCE %	ROE %	Rev CAGR 5Y %	Profit CAGR 5Y %
1	IRTC iRhythm Holdings, Inc. R2K	113.90	-	$3.74B	-	-3.51%	-22.42%	22.05%	20.55%
2	LLY Eli Lilly and Company SPX	1,105.00	39.21	$985.37B	0.63%	38.44%	107.46%	31.69%	48.96%
3	JNJ Johnson & Johnson SPX	225.33	26.11	$542.42B	2.38%	23.13%	26.42%	5.60%	14.32%
4	UNH UnitedHealth Group Incorporated SPX	380.31	28.66	$345.38B	2.32%	9.60%	12.18%	11.35%	-15.69%
5	MRK Merck & Co., Inc. SPX	118.72	33.44	$293.22B	2.86%	20.66%	18.94%	3.12%	7.93%
6	TMO Thermo Fisher Scientific Inc. SPX	492.51	27.11	$183.03B	0.38%	9.17%	13.52%	-0.27%	-1.19%
7	AMGN Amgen Inc. NDXSPX	336.79	23.42	$181.77B	2.99%	18.02%	101.32%	11.77%	5.58%
8	GILD Gilead Sciences, Inc. NDXSPX	134.43	18.29	$166.90B	2.44%	22.92%	43.36%	2.57%	22.83%
9	ISRG Intuitive Surgical, Inc. NDXSPXAI	424.64	51.53	$150.39B	-	15.96%	17.23%	17.39%	29.26%

Quarterly Results

Figures in USD.

Metric	Sep 2015	Dec 2015	Mar 2016	Jun 2016	Sep 2016	Dec 2016	Mar 2017	Jun 2017	Sep 2017	Dec 2017	Mar 2018	Jun 2018	Sep 2018	Dec 2018	Mar 2019	Jun 2019	Sep 2019	Dec 2019	Mar 2020	Jun 2020	Sep 2020	Dec 2020	Mar 2021	Jun 2021	Sep 2021	Mar 2022	Jun 2022	Sep 2022	Mar 2023	Jun 2023	Sep 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Revenue	-	-	-	-	-	-	21.44M	23.85M	25.04M	28.18M	31.76M	35.29M	38.44M	41.78M	48.33M	52.44M	54.67M	59.10M	63.53M	50.88M	71.94M	78.81M	74.31M	81.28M	85.43M	92.38M	102.05M	103.88M	111.44M	124.13M	124.60M	131.93M	148.05M	-	-	158.68M	186.69M	192.88M	208.89M	199.39M
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	49.46M	53.83M	55.76M	60.84M	58.04M
Gross Profit	5.60M	6.69M	8.20M	10.58M	11.50M	12.92M	15.10M	17.11M	18.11M	20.48M	23.21M	25.81M	28.49M	30.98M	36.56M	39.43M	40.89M	45.19M	47.47M	35.39M	53.71M	58.31M	50.85M	55.28M	56.15M	61.76M	70.25M	70.92M	75.68M	86.22M	82.47M	87.52M	103.47M	-	-	109.22M	132.86M	137.12M	148.06M	141.35M
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	141.77M	149.09M	145.55M	143.79M	157.54M
Operating Income	-5.50M	-	-4.87M	-3.70M	-2.67M	-	-4.75M	-5.92M	-5.98M	-	-10.60M	-12.78M	-9.22M	-	-8.20M	-10.56M	-18.26M	-	-9.17M	-20.16M	-4.76M	-	-27.47M	-16.99M	-23.28M	-48.55M	-23.45M	-21.09M	-39.50M	-18.87M	-27.60M	-38.14M	-22.98M	-	-	-32.56M	-16.23M	-8.43M	4.26M	-16.18M
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-20.95M	-5.37M	3.97M	18.39M	-4.41M
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2.48M	2.51M	2.54M	5.63M	2.48M
Pretax Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-30.04M	-14.40M	-5.19M	6.03M	-13.43M
Tax Provision	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	665.00K	-183.00K	24.00K	447.00K	500.00K
Net Income	-5.75M	-7.70M	-6.13M	-4.44M	-4.08M	-6.27M	-5.30M	-6.44M	-6.52M	-11.15M	-11.08M	-13.30M	-9.73M	-16.27M	-8.25M	-10.72M	-18.29M	-17.30M	-9.06M	-20.44M	-4.68M	-9.65M	-27.78M	-17.36M	-23.73M	-50.61M	-23.90M	-21.45M	-39.11M	-18.48M	-27.12M	-45.67M	-20.11M	-	-	-30.70M	-14.22M	-5.21M	5.58M	-13.93M
Diluted EPS	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-0.75	-0.17	-	-0.95	-0.59	-0.81	-1.71	-0.80	-0.71	-1.29	-0.61	-0.89	-1.47	-0.65	-	-	-0.97	-0.44	-0.16	0.17	-0.43
R&D Expense	1.65M	-	1.54M	1.67M	1.64M	-	2.62M	2.78M	3.79M	-	4.04M	4.65M	5.09M	-	6.70M	7.83M	13.50M	-	8.41M	12.54M	8.77M	-	8.51M	9.61M	8.69M	10.54M	11.95M	11.45M	14.84M	13.68M	16.31M	16.99M	19.69M	-	-	-	-	-	-	-

Profit & Loss (Annual)

Figures in USD.

Metric	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Revenue	-	-	64.07M	99.13M	147.28M	214.55M	265.17M	-	410.92M	492.68M	591.84M	747.14M
Cost of Revenue	-	-	-	-	-	-	-	-	129.29M	160.88M	184.31M	219.89M
Gross Profit	11.16M	21.44M	43.19M	70.93M	108.48M	162.07M	194.89M	-	281.63M	331.81M	407.53M	527.25M
Operating Expenses	-	-	-	-	-	-	-	-	368.81M	445.89M	522.39M	580.20M
Operating Income	-14.77M	-21.63M	-15.58M	-27.59M	-45.69M	-54.76M	-43.67M	-	-87.18M	-114.08M	-114.86M	-52.95M
EBITDA	-	-	-	-	-	-	-	-	-92.14M	-96.86M	-74.13M	-3.96M
Interest Expense	-	-	-	-	-	-	-	-	4.14M	3.65M	12.82M	13.15M
Pretax Income	-	-	-	-	-	-	-	-	-115.89M	-122.66M	-112.72M	-43.60M
Tax Provision	-	-	-	-	-	-	-	-	269.00K	750.00K	565.00K	953.00K
Net Income	-15.83M	-22.80M	-20.90M	-29.74M	-50.38M	-54.57M	-43.83M	-	-116.16M	-123.41M	-113.29M	-44.55M
Diluted EPS	-	-	-	-	-	-2.16	-1.58	-	-3.88	-4.04	-3.63	-1.39
R&D Expense	5.70M	6.35M	7.15M	13.27M	20.86M	37.30M	41.33M	38.67M	46.61M	60.24M	-	-

Compounded Sales Growth

5 Years:	22.05%
1 Year:	25.70%

Compounded Profit Growth

5 Years:	20.55%
1 Year:	-

Stock Price Performance

1 Year:	-18.93%
6 Months:	-39.51%
3 Months:	-14.84%
1 Month:	-5.67%

Balance Sheet (Annual)

Figures in USD.

Metric	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Assets	-	-	37.87M	138.16M	133.12M	117.52M	306.21M	511.74M	-	448.22M	433.14M	931.45M	1.02B
Current Assets	-	-	-	-	-	-	-	-	-	288.77M	230.81M	645.82M	702.76M
Cash & Equivalents	7.10M	8.62M	25.21M	51.64M	8.67M	20.02M	20.46M	88.63M	-	78.83M	36.17M	419.60M	236.01M
Inventory	-	-	-	-	-	-	-	-	-	15.15M	13.97M	14.04M	21.63M
Receivables	-	-	-	-	-	-	-	-	-	49.92M	61.48M	79.94M	75.71M
Total Liabilities	-	-	42.40M	45.59M	53.57M	65.39M	170.80M	170.13M	-	208.41M	223.05M	840.54M	867.30M
Current Liabilities	-	-	8.78M	13.21M	20.92M	30.33M	52.07M	65.67M	-	89.10M	107.37M	110.92M	151.89M
Long Term Debt	-	-	30.55M	32.23M	32.49M	34.90M	-	-	-	34.94M	34.95M	646.44M	649.50M
Total Debt	-	-	-	-	-	-	-	-	-	131.04M	129.82M	736.91M	731.18M
Total Equity	-65.59M	-80.54M	-101.62M	93.04M	79.34M	52.14M	135.41M	341.61M	-	239.81M	210.10M	90.91M	152.75M
Shares Outstanding	-	-	-	-	-	-	-	-	-	30.19M	30.95M	31.62M	32.53M

Cash Flows (Annual)

Figures in USD.

Metric	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Operating Cash Flow	-	-	-16.65M	-14.91M	-29.09M	-21.86M	-13.76M	-	-23.01M	-50.10M	3.39M	80.86M
Investing Cash Flow	-	-	-68.17M	-34.68M	34.14M	-89.27M	-132.39M	-	-52.43M	-1.21M	-122.98M	-277.06M
Financing Cash Flow	-	-	111.25M	6.53M	6.30M	111.58M	214.32M	-	26.72M	8.82M	511.38M	12.61M
Capital Expenditure	-539.00K	-1.79M	-2.76M	-3.56M	-5.18M	-20.46M	-13.55M	-	-29.83M	-40.42M	-48.94M	-46.34M
Free Cash Flow	-	-	-19.41M	-18.47M	-34.27M	-42.32M	-27.31M	-	-52.84M	-90.53M	-45.55M	34.52M
Net Change in Cash	-	-	-	-	-	-	-	-	-48.73M	-42.49M	391.79M	-183.59M
Share Buybacks	-	-	-	-	-	-	-	-	0	0	25.00M	0

Ratios (Annual)

Figures in %.

Metric	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Gross Margin %	-	-	67.4%	71.5%	73.7%	75.5%	73.5%	-	68.5%	67.3%	68.9%	70.6%
Operating Margin %	-	-	-24.3%	-27.8%	-31.0%	-25.5%	-16.5%	-	-21.2%	-23.2%	-19.4%	-7.1%
Net Margin %	-	-	-32.6%	-30.0%	-34.2%	-25.4%	-16.5%	-	-28.3%	-25.0%	-19.1%	-6.0%
ROE %	19.7%	22.4%	-22.5%	-37.5%	-96.6%	-40.3%	-12.8%	-	-48.4%	-58.7%	-124.6%	-29.2%
ROCE %	-	-74.3%	-12.5%	-24.6%	-52.4%	-21.5%	-9.8%	-	-24.3%	-35.0%	-14.0%	-6.1%

Shareholding Pattern

Insiders

1.12%

Institutions

110.95%

Public Float

112.21%

Top Institutional Holders

#	Holder	% Held	Shares	Value
1	Blackrock Inc.	8.34%	2.74M	$312.26M
2	Vanguard Portfolio Management LLC	5.47%	1.80M	$204.61M
3	RTW Investments LP	5.08%	1.67M	$190.04M
4	Millennium Management Llc	4.89%	1.61M	$183.15M
5	Artisan Partners Limited Partnership	4.42%	1.45M	$165.26M
6	Vanguard Capital Management LLC	4.40%	1.45M	$164.67M
7	FMR, LLC	4.14%	1.36M	$155.12M
8	Holocene Advisors, LP	3.80%	1.25M	$142.22M
9	UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC	3.19%	1.05M	$119.30M
10	Geode Capital Management, LLC	2.49%	817.11K	$93.07M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for IRTC

No recent headlines available.

IRTC · Healthcare